Contemporary therapy of acute ST-elevation myocardial infarction

Texas Heart Institute Journal

Volumn 36, Issue 4, 2009, Pages 273-281

  Armstrong, Paul W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angioplasty, transluminal, percutaneous coronary standards; Clinical protocols; Community health planning; Electrocardiography; Fibrinolysis; Fibrinolytic agents; Myocardial infarction therapy; Myocardial reperfusion; Risk assessment; Risk reduction behavior; Thrombolytic therapy; Time factors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENOXAPARIN; EPTIFIBATIDE; EZETIMIBE; FIBRIC ACID DERIVATIVE; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; NAPROXEN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PARACETAMOL; PROTON PUMP INHIBITOR; RETEPLASE; REVIPARIN; TENECTEPLASE; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG;

ACUTE HEART INFARCTION; ARTHRALGIA; BARE METAL STENT; BLOOD CLOT LYSIS; CLINICAL TRIAL; DEFIBRILLATOR; DIABETES MELLITUS; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG ELUTING STENT; EDEMA; ELECTROCARDIOGRAPHY; EMERGENCY HEALTH SERVICE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REPERFUSION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTENSIVE CRISIS; KIDNEY DYSFUNCTION; LOW DRUG DOSE; LUNG EDEMA; MORTALITY; MUSCULOSKELETAL PAIN; OBESITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PREDICTION; Q WAVE; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SECONDARY PREVENTION; SHOCK; ST ELEVATION MYOCARDIAL INFARCTION; ST SEGMENT ELEVATION; TACHYCARDIA; THERAPY EFFECT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

CARDIOVASCULAR AGENTS; CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; QUALITY ASSURANCE, HEALTH CARE; RECURRENCE; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 69949103171     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44(3):E1-211.
2. Jacobs AK. Regional systems of care for patients with ST-elevation myocardial infarction: being at the right place at the right time. Circulation 2007;116(7):689-692 (Pubitemid 47255984)
3. Shavelle DM, Rasouli ML, Frederick P, Gibson CM, French WJ. Outcome in patients transferred for percutaneous coronary intervention (a national registry of myocardial infarction 2/3/4 analysis). Am J Cardiol 2005;96(9):1227-1232 (Pubitemid 41505398)
4. Armstrong PW, Westerhout CM, Welsh RC. Duration of symptoms is the key modulator of the choice of reperfusion for ST-elevation myocardial infarction. Circulation 2009;119 (9):1293-1303
5. Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003;108(23):2851-2856 (Pubitemid 37517811)
6. Armstrong PW. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J 2006;27(13):1530-1538
7. Danchin N, Coste P, Ferrieres J, Steg PG, Cottin Y, Blanchard D, et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the French registry on acute ST-elevation myocardial infarction (FAST-MI). Circulation 2008;118(3):268-276
8. Ting HH, Rihal CS, Gersh BJ, Haro LH, Bjerke CM, Lennon RJ, et al. Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation 2007;116(7): 729-736
9. Wong CK, Gao W, Raffel OC, French JK, Stewart RA, White HD. Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2. Lancet 2006;367(9528):2061-2067 (Pubitemid 43913985)
10. Armstrong PW, Fu Y, Westerhout CM, Hudson MP, Mahaffey KW, White HD, et al. Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2009; 53(17):1503-1509
11. Welsh RC, Ornato J, Armstrong PW. Prehospital management of acute ST-elevation myocardial infarction: a time for reappraisal in North America. Am Heart J 2003;145(1):1-8. (Pubitemid 36034489)
12. Armstrong PW, Collen D. Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. Circulation 2001;103(23):2862-2866 (Pubitemid 32550078)
13. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006;367(9510):569-578 (Pubitemid 43247572)
14. Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, et al. Facilitated PCI in patients with STelevation myocardial infarction. N Engl J Med 2008;358(21): 2205-2217 (Pubitemid 351724450)
15. Di Mario C, Dudek D, Piscione F, Mielecki W, Savonitto S, Murena E, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 2008;371(9612):559-568 (Pubitemid 351232030)
16. Cantor WJ. Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Presented at the SCAI-ACC i2 Summit/American College of Cardiology 57th Annual Scientific Session (Chicago), 2008 Mar 30 [cited 2008 May 19]. Available from: http://www.cardiosource.com/rapidnews summaries/acc08.asp or from http://www.cardiosource.com/ cvn/index.asp?videoid=412 or from http://www.cardiosource. com/clinicaltrials/trial.asp?trialID=1661.
17. Armstrong PW, Collen D, Antman E. Fibrinolysis for acute myocardial infarction: the future is here and now. Circulation 2003;107(20):2533-2537 (Pubitemid 36628929)
18. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29(23):2909-2945
19. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 Focused Update of the ACC/ AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee [published erratum appears in Circulation 2008;117(2):e162]. Circulation 2008;117(2):296-329.
20. Yusuf S, Mehta SR, Xie C, Ahmed RJ, Xavier D, Pais P, et al. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005;293(4):427-435
21. Yusuf S, Mehta SR, Chrolavicius S, Azfal R, Pogue J, Granger CB, et al. Effects of fondaparinux on mortality and reinfarc tion in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295 (13):1519-1530
22. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358(21):2218-2230 (Pubitemid 351724451)
23. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115(12):1634- 1642 (Pubitemid 46648649)
24. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008;118(18):1894-1909
25. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000;102(17):2031-2037 (Pubitemid 30786479)
26. Morrow DA, Antman EM, Parsons L, de Lemos JA, Cannon CP, Giugliano RP, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA 2001;286(11):1356-1359 (Pubitemid 33015527)
27. Thune JJ, Hoefsten DE, Lindholm MG, Mortensen LS, Andersen HR, Nielsen TT, et al. Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty. Circulation 2005;112(13):2017-2021
28. Krumholz HM, Anderson JL, Bachelder BL, Fesmire FM, Fihn SD, Foody JM, et al. ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to develop performance measures for ST-elevation and non-ST-elevation myocardial infarction): developed in collaboration with the American Academy of Family Physicians and the American College of Emergency Physicians: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine. Circulation 2008;118(24): 2596-2648
29. Thomas RJ, King M, Lui K, Oldridge N, Pina IL, Spertus J, et al. AACVPR/ACC/AHA 2007 performance measures on cardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary prevention services endorsed by the American College of Chest Physicians, American College of Sports Medicine, American Physical Therapy Association, Canadian Association of Cardiac Rehabilitation, European Association for Cardiovascular Prevention and Rehabilitation, Inter-American Heart Foundation, National Association of Clinical Nurse Specialists, Preventive Cardiovascular Nurses Association, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2007;50(14):1400-1433